Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas

NCT01914510 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT01914510
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01914510 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase II Study of Oral ENMD-2076 Administered to Patients With Ovarian Clear Cell Carcinomas
Lead sponsor
University Health Network, Toronto
Phase
Phase 2
Overall status
Completed
Start date
September 30, 2013
Completion date
January 31, 2017
Enrollment
40 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

ovarian clear cell carcinoma